The Journal of Targeted Therapies in Cancer

The concept of cancer immunotherapy— using the patient’s immune system to target and eradicate cancer—has evolved over more than a century of research.
The combination of surgery, radioactive iodine (RAI), and L-thyroxine therapy is effective treatment for patients with differentiated thyroid cancer (DTC), which accounts for some 95% of all thyroid cancers.
The liver is a common site of metastatic recurrence for many tumors. For a minority of patients, surgical resection may be an option; however, most patients will not qualify for surgery due to insufficient liver functional reserve or other contraindications.
In an interview with Targeted Therapies, Wierda discussed new treatments for CLL, including issues in translating these regimens into clinical practice.
Amid advances in targeted therapies for patients with chronic lymphocytic leukemia (CLL), researchers also have been making strides in the realm of chemoimmunotherapy regimens for the disease.
Despite initial clinical benefit of erlotinib and geftinib, overall efficacy of these agents is limited by emergence of drug-resistance mutations, including the gatekeeper T790M mutation.
Advanced gastric cancer and gastroesophageal junction cancers are highly aggressive cancers with poor prognosis and limited treatment options. The VEGF pathway has been one of the key signaling pathways under investigation for these cancers.
JTT Articles
A Long-Awaited Treatment Option for Radioiodine- Refractory DTC
The Transformation of Treatment in CLL: A Q & A With Dr. William G. Wierda
A Q&A With Richard Finn, MD: Targeted Therapies for Breast Cancer
External Resources

Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Targeted Communications
Connect With Us:

About Us
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.